Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

What is claimed is:

1. (previously presented): A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of formula (I):



(I)

wherein:

R^2 is H, F, Cl, Br, I, cyano, nitro, COR^a, $COOR^a$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene; wherein R^a is H, C_{1-6} alkyl, C_{3-7} cycloalkyl, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene;

R^3 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene

or R^2 and R^3 taken together with the phenyl ring to which they are attached form a naphthyl;

R^4 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, COR^b, $COOR^b$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene; wherein R^b is H, C_{1-6} alkyl, C_{3-7} cycloalkyl, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene;

R^5 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, or C_{3-7} cycloalkyl;

R^6 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene;

X is NH, O, or CH_2;

W is S, O, or =N-CN;

each of R^7 and R^8 is independently selected from H, C_{1-6} alkyl, C_{3-7} cycloalkyl, (C_{3-7} cycloalkyl)-C_{1-6} alkylene, phenyl, and (phenyl)-C_{1-6} alkylene, provided at least one of R^7 and R^8 is not H;

wherein each of the above hydrocarbyl or heterocarbyl moieties can be optionally substituted with between 1 and 3 substituents selected from F, Cl, Br, I, cyano, hydroxy, nitro, amino, COR^c, $COOR^c$, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, C_{1-3} haloalkyl, and C_{3-6} cycloalkyl; wherein R^c is H or C_{1-6} alkyl;

provided when W is O, X is NH, and R^7 and R^8 are each methyl, and R^3, R^4, R^5, and R^6 are each H, then R^2 is not H, 2-chlorophenyl, or 3-quinolinyl;

and pharmaceutically acceptable salts, esters, amides, and hydrates thereof.

2. (previously presented): A composition of claim 1, wherein W is O.

3. (previously presented): A composition of claim 1, wherein R^2 and R^4 are not hydrogen.

4. (previously presented): A composition of claim 1, wherein X is CH_2.

5. (previously presented): A composition of claim 1, wherein X is NH.

6. (previously presented): A composition of claim 1, wherein each of R^7 and R^8 is independently selected from methyl, ethyl, and propyl.

7. (previously presented): A composition of claim 1, wherein at least two of R^3, R^5, and R^6 are H.

8. (previously presented): A composition of claim 1, wherein R^2 is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C_{2-9} heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.

9. (previously presented): A composition of claim 8, wherein R^2 is Cl, Br, I, methyl, cyano, C_{2-9} heteroaryl, phenyl, or phenyl substituted with hydroxy, thiol, or halo.

10. (previously presented): A composition of claim 1, wherein R^3 is H or methyl.

11. (previously presented): A composition of claim 10, wherein R^3 is H.

12. (previously presented): A composition of claim 1, wherein R^4 is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C_{2-9} heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.

13. (previously presented): A composition of claim 12, wherein R^4 is H, Cl, Br, I, or methyl.

14. (previously presented): A composition of claim 1, wherein R^5 is H, Cl, Br, I, methyl, halomethyl, methoxy, thiomethyl, ethyl, ethoxy, or thioethyl.

15. (previously presented): A composition of claim 14, wherein R^5 is H, methyl, or Cl.

16. (previously presented): A composition of claim 1, wherein the stereochemistry of the two dioxane chiral centers is (S,S).

17. (previously presented): A composition of claim 1, wherein said compound of formula (I) is selected from: 1-(2-Bromo-phenyl)-3-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-Biphenyl-2-yl-3-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
1-(2,3-Dichloro-phenyl)-3-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

18. (previously presented): A composition of claim 1, wherein said compound of formula (I) is selected from: 1-(4-Bromo-2-chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2,4-Dibromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2,4-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Chloro-5-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-2-yl-phenyl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-iodo-phenyl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(4-iodo-phenyl)-urea;
1-(4-Bromo-2-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Bromo-4-methyl-phenyl)-3-((4S, 5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

1-(2-Cyano-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(3'-Chloro-biphenyl-2-yl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2,5-Dimethyl-phenyl)-3-((4S, 5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
1-Biphenyl-2-yl-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

19. (previously presented): A composition of claim 1, wherein said compound of formula (I) is selected from: 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-trifluoromethyl-phenyl)-urea;
1-(4-Bromo-3-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)- urea;
1-(2-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2,5-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Chloro-5-trifluoromethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Bromo-phenyl)-3-((4R,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-3-yl-phenyl)-urea.

20. (previously presented): A composition of claim 1, wherein said compound of formula (I) is selected from: 1-(2,4-Dimethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-fluoro-phenyl)-urea;

1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-*o*-tolyl-urea;

1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-nitro-phenyl)-urea;

2-(2-Bromo-phenyl)-N-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-acetamide;

((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-carbamic acid 2-chloro-phenyl ester;

1-(4-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-methoxy-phenyl)-urea;

1-(4-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid;

2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid methyl ester;

1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-isopropyl-phenyl)-urea;

1-(2,6-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

1-(3-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

1-(2,4-Difluoro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and

1-(3-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

21. (previously presented): A compound of formula (Ia):



(Ia)

wherein:

R^2 is H, F, Cl, Br, I, cyano, nitro, COR^a, $COOR^a$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene; wherein R^a is H, C_{1-6} alkyl, C_{3-7} cycloalkyl, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene;

R^3 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene

or R^2 and R^3 taken together with the phenyl ring to which they are attached form a naphthyl;

R^4 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, COR^b, $COOR^b$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene; wherein R^b is H, C_{1-6} alkyl, C_{3-7} cycloalkyl, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene;

R^5 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, or C_{3-7} cycloalkyl;

R^6 is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, C_{2-9} heterocyclyl, (phenyl)-C_{1-6} alkylene, (C_{2-9} heterocyclyl)-C_{1-6} alkylene, or (C_{3-7} cycloalkyl)-C_{1-6} alkylene;

X is NH, O, or CH_2;

W is S, O, or =N-CN;

each of R^7 and R^8 is independently selected from H, C_{1-6} alkyl, C_{3-7} cycloalkyl, (C_{3-7} cycloalkyl)-C_{1-6} alkylene, phenyl, and (phenyl)-C_{1-6} alkylene, provided at least one of R^7 and R^8 is not H;

wherein each of the above hydrocarbyl or heterocarbyl moieties can be optionally substituted with between 1 and 3 substituents selected from F, Cl, Br, I, cyano, hydroxy, nitro, amino, COR^c, $COOR^c$, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, C_{1-3} haloalkyl, and C_{3-6} cycloalkyl; wherein R^c is H or C_{1-6} alkyl;

provided when W is O, X is NH, and R^7 and R^8 are each methyl, and R^3, R^4, R^5, and R^6 are each H, then R^2 is not H, Br, phenyl, 2-chlorophenyl, or 3-quinolinyl;

provided when W is O, X is NH, and R^7 and R^8 are each methyl, and R^4, R^5, and R^6 are each H, then R^3 is not Cl nor is R^3 taken together with R^2; and

provided when W is O, X is NH, and R^7 and R^8 are each methyl, and R^2, R^5, and R^6 are each H, then R^4 is not Cl;

and pharmaceutically acceptable salts, esters, amides, and hydrates thereof.

22. (previously presented): A compound of claim 21, wherein W is O.

23. (previously presented): A compound of claim 21, wherein R^2 and R^4 are not hydrogen.

24. (previously presented): A compound of claim 21, wherein X is CH_2.

25. (previously presented): A compound of claim 21, wherein X is NH.

26. (previously presented): A compound of claim 21, wherein each of R^7 and R^8 is independently selected from methyl, ethyl, and propyl.

27. (previously presented): A compound of claim 21, wherein at least two of R^3, R^5, and R^6 are H.

28. (previously presented): A compound of claim 21, wherein R^2 is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C_{2-9} heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.

29. (previously presented): A compound of claim 28, wherein R^2 is Cl, Br, I, methyl, cyano, C_{2-9} heteroaryl, phenyl, or phenyl substituted with hydroxy, thiol, or halo.

30. (previously presented): A compound of claim 21, wherein R^3 is H or methyl.

31. (previously presented): A compound of claim 30, wherein R^3 is H.

32. (previously presented): A compound of claim 21, wherein R^4 is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C_{2-9} heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.

33. (previously presented): A compound of claim 32, wherein R^4 is H, Cl, Br, I, or methyl.

34. (previously presented): A compound of claim 21, wherein R^5 is H, Cl, Br, I, methyl, halomethyl, methoxy, thiomethyl, ethyl, ethoxy, or thioethyl.

35. (previously presented): A compound of claim 34, wherein R^5 is H, methyl, or Cl.

36. (previously presented): A compound of claim 21, wherein the stereochemistry of the two chiral centers is (S,S).

37. (previously presented): A compound of claim 21, wherein said compound of formula (Ia) is selected from: 1-(4-Bromo-2-chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2,4-Dibromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2,4-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Chloro-5-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-2-yl-phenyl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-iodo-phenyl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(4-iodo-phenyl)-urea;
1-(4-Bromo-2-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Bromo-4-methyl-phenyl)-3-((4S, 5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Cyano-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(3'-Chloro-biphenyl-2-yl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
1-(2,5-Dimethyl-phenyl)-3-((4S, 5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

38. (previously presented): A compound of claim 21, wherein said compound of formula (Ia) is selected from: 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-trifluoromethyl-phenyl)-urea;

1-(4-Bromo-3-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)- urea;
1-(2,5-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Chloro-5-trifluoromethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-3-yl-phenyl)-urea.

39. (previously presented): A compound of claim 21, wherein said compound of formula (Ia) is selected from: 1-(2,4-Dimethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(2-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-fluoro-phenyl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-*o*-tolyl-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-nitro-phenyl)-urea;
2-(2-Bromo-phenyl)-N-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-acetamide;
((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-carbamic acid 2-chloro-phenyl ester;
1-(4-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-methoxy-phenyl)-urea;
2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid;
2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid methyl ester;
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-isopropyl-phenyl)-urea;

1-(2,6-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
1-(3-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
1-(2,4-Difluoro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

40. (previously presented): A method for treating obesity, said method comprising administering to a subject a pharmaceutically-effective amount of a pharmaceutical composition of claim 1.

41. (previously presented): A method for treating a sleep/wake disorder, said method comprising administering to a subject a pharmaceutically-effective amount of a pharmaceutical composition of claim 1.

42. (previously presented): A method of claim 41, wherein said sleep/wake disorder is selected from insomnia, narcolepsy, jet lag, and sleep apnea.

43. (canceled): A method for treating a disease or condition mediated by an orexin-2 receptor, said method comprising administering to a subject a pharmaceutically-effective amount of a pharmaceutical composition of claim 1.

44. (canceled): A method for inhibiting an orexin-2 receptor, said method comprising contacting said receptor with a compound of claim 1.

45. (canceled): A method of claim 44, wherein said orexin-2 receptor is human.

46. (currently amended): A ~~method~~ compound of claim 21 ~~44~~, wherein said compound is selective for orexin-2 receptor over orexin-1 receptor by a factor of at least 10.

47. (currently amended): A ~~method~~ compound of claim 46, wherein said factor is at least 100.